钆滞留作为安全信号:一家生产商的经历
本文回顾了2014年Kanda等首次报道多次注射钆基对比剂后脑内钆滞留以来,各监管机构相继采取的行动与决策。所有监管机构均认为无证据表明钆滞留对人体有害,但基于相同的临床前和临床证据,各机构在标签、上市许可及对生产商要求上采取了不同做法。生产商需适应不同监管立场并提供相应证据,同时持续监测产品的获益-风险平衡。
要点
- 所有监管机构一致认为,目前无证据表明钆滞留对人体产生有害效应。
- 各监管机构基于相同证据对钆基对比剂的标签和上市许可采取了不同决策。
- 生产商需按不同国家监管要求开展特定临床前和临床研究并提供证据。
核心结论
- 各监管机构均认为无证据表明钆滞留对人体有害,但因监管立场不同而对钆基对比剂采取了不同的标签和上市许可决策,生产商需适应并持续监测获益-风险平衡。
研究设计与样本
- 本文为综述,回顾2014年起各监管机构对钆基对比剂钆滞留问题采取的行动与决策,并按地区汇总;同时呈现2018年各地区和主要国家的钆基对比剂销售量作为患者暴露指标。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this manuscript is to review the successive regulatory actions and decisions following the initial publication by Kanda and colleagues in 2014 regarding gadolinium retention in the human brain after multiple gadolinium-based contrast agents (GBCAs) administrations.
MATERIALS AND METHODS: Starting from 2014, the actions and decisions made by all regulatory authorities were collected and summarized region by region. Volumes of GBCA sales in 2018 per region and main countries are also presented as an indicator of patients' exposure to those products.
RESULTS: All regulatory authorities agreed on the absence of evidence of any harmful effect of gadolinium retention in humans. However, based on the same amount of preclinical and clinical evidence available in adults and children, regulatory authorities used different approaches resulting in different actions and decisions regarding the labeling and market authorizations of GBCAs, as well as the specific actions requested to the manufacturers.
CONCLUSIONS: The manufacturers of GBCAs had to face different situations according to the countries, due to the different positions and expectations from regulatory agencies. They have adapted their responses to the different positions of the regulatory agencies and conducted specific preclinical and clinical investigations to provide the expected evidence. It is also their responsibility to continuously monitor the benefit-risk balance of the products and to propose risk minimization measures to the regulatory agencies.
引用
- Lancelot E, Desché P. Gadolinium Retention as a Safety Signal: Experience of a Manufacturer. Invest Radiol. 2020. PMID: 31725063. doi:10.1097/RLI.0000000000000605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。